Clinical Trial Update: Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lenalidomide versus placebo maintenance after induction therapy in newly diagnosed multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED